The future of high-risk prostate cancer treatment is taking shape — and the PCCTC is proud to be at the forefront! www.linkedin.com/posts/prosta...

Dr Tanya B. Dorff has been selected to present the PCCTC multicenter phase 1 first-in-human study evaluating the first-in-class PSMA/STEAP1 dual-targeting antibody drug conjugate ABBV-969 in patients with mCRPC during the Rapid Oral Abstract Session at #ASCO26 www.asco.org/abstracts-pr...

The PCCTC is proud to highlight that our colleague and dear friend Mary-Ellen Taplin, MD, FASCO has been selected to present at the Plenary Session at #ASCO26 where she will present the final analysis of the PROTEUS phase 3 study www.asco.org/abstracts-pr...

PCCTC Investigator Andrew J. Armstrong, MD, MS Selected for Rapid Oral Abstract Session at #ASCO26: www.linkedin.com/pulse/pcctc-...

#ASCO26 abstracts are now live and we are pleased to announce 13 prostate cancer abstracts representing PCCTC science spanning radioligand therapies, PARP inhibition, immunotherapy, biomarker-driven design, NEPC, and health equity will be presented!

First Patient Enrolled at Memorial Sloan Kettering Cancer Center in PCCTC-Sponsored TALENT Study Evaluating (NCT06844383) Novel Treatment Combination for Advanced Prostate Cancer: www.pcctc.org/news/first-p...

Results of the Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE) led by the PCCTC’s Dr. Rana McKay published in JCO: ascopubs.org/doi/pdf/10.1...

PCCTC investigator and PCWG4 co-primary author Dr Andrew Armstrong: PCWG4 Amends Terminology and Biomarker Standards for Advanced Prostate Cancer www.urotoday.com/video-lectur...

PCCTC Investigator and 2025 PCF Lifetime Achievement Award for Women in Science recipient Dr Maha Hussain on lessons from a career in prostate cancer clinical trial leadership: www.urotoday.com/video-lectur...

PCCTC investigator @dangeorgemd.bsky.social on individualized goals and shared decision-making in mHSPC care via UroToday: www.urotoday.com/video-lectur...

First quadruplet therapy regimen shows promise for men with metastatic high-volume metastatic androgen pathway modulation–naïve prostate cancer. CASCARA clinical trial results published in Clinical Cancer Research: www.pcctc.org/news/first-q...

PCCTC investigator @dangeorgemd.bsky.social on emerging concepts in detecting and treating prostate cancer via Diagnostic Imaging: www.diagnosticimaging.com/view/emergin...

Dr @seanmmcbride.bsky.social on the PCCTC-managed AASUR Trial in High-Risk Prostate Cancer via @oncodaily.bsky.social: oncodaily.com/voices/sean-...

Advancing the Standard: How the PCCTC Led the Science at the 2026 ASCO GU Symposium and Forged New Paths for Collaboration www.linkedin.com/pulse/advanc...

PCCTC SOC Chair and PCWG4 Co-Lead Author @mjmorrismd.bsky.social discusses Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 with @oncoalert.bsky.social www.linkedin.com/feed/update/...

‼️#GU26 simultaneous publication by @AarmstrongDuke et al:  Trial Design and Objectives for Patients with Prostate Cancer: Recommendations From Prostate Cancer Working Group 4 Learn more: https://bit.ly/46dupmq

PCCTC investigator and PCWG4 co-lead author Dr Andrew J. Armstrong discusses the new prostate cancer trial design recommendations with OncoAlert: www.linkedin.com/feed/update/...

Just published! Prostate Cancer Working Group 4 recommendations are now available in the Journal of Clinical Oncology, providing updated standards for clinical trial design, patient eligibility, and outcome measures in advanced prostate cancer: ascopubs.org/doi/pdfdirec...

We’re excited to highlight the groundbreaking research being shared tomorrow by PCCTC investigators at #GU26! From cutting-edge clinical trial results to revised PCWG4 guidelines, these abstracts showcase the passion and progress driving the future of prostate cancer care.

K36 Therapeutics Highlights PCCTC-managed First-in-Human KTX-2001 Prostate Cancer Study Design at #GU26 www.prnewswire.com/news-release...

Prostate Cancer Working Group 4: What Does Its Work Mean for the Busy Clinician? #ASCODailyNews speaks with PCCTC investigators Drs Michael Morris and Andrew Armstrong: dailynews.ascopubs.org/do/prostate-...

PCCTC Investigator Dr. Maha Hussain to Present BRCAAway Prostate Cancer Trial Results at #GU26 Showing Median Survival Exceeding 5 Years with Abiraterone Plus Olaparib www.pcctc.org/news/landmar...

We are pleased to announce the first public presentation of updated global standards for advanced prostate cancer clinical trials, Prostate Cancer Working Group 4 (PCWG4), at #GU26: www.pcctc.org/news/prostat...

PCCTC Investigators To Showcase Groundbreaking Prostate Cancer Research at 2026 ASCO GU Symposium (#GU26): www.pcctc.org/news/pcctc-i...

The Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group Criteria (#PCWG4) with guests PCCTC SOC chair @mjmorrismd.bsky.social and PCCTC investigator Dr Andrew Armstrong: creators.spotify.com/pod/profile/...

K36 Therapeutics Completes Dosing of First Cohort in PCCTC-Managed Phase 1 Clinical Trial of NSD2 Inhibitor KTX-2001 in Prostate Cancer www.prnewswire.com/news-release...

PCCTC investigators Drs. Mary-Ellen Taplin and Andrew Armstrong discuss ASCO's first living guidelines for prostate cancer: www.oncologynewscentral.com/prostate-can...

In an effort by PCCTC investigators and colleagues, the importance of racial diversity in future genomic profiling and clinical trials efforts is highlighted. Full manuscript: pmc.ncbi.nlm.nih.gov/articles/PMC...

PCCTC investigator @dangeorgemd.bsky.social of Duke University discusses the role of radioligand therapy in prostate cancer management: www.onclive.com/view/dr-geor...

The PCCTC plans on hiring three summer interns to support our Data Management, Data Science, and Clinical Operations teams. The 10-week internships are full-time, paid, 100% remote, and working hours are 9-5 EST. To learn more visit www.pcctc.org/news/2026-su...

Prostate Cancer Clinical Trials Consortium (PCCTC) Innovation Featured at Biocom California’s “Innovations in Oncology Clinical Trial Design” Forum www.linkedin.com/pulse/prosta...

Just published - DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis www.nature.com/articles/s41...

The PCCTC's phase 2 study of talazoparib with or without enzalutamide in patients With metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate (TALENT) is now actively enrolling. To learn more visit clinicaltrials.gov/study/NCT068...

The first site for the first-in-human KTX-2001 STRIKE-001 prostate cancer study has been activated at USA Clinical Trials (San Antonio, TX)—setting a PCCTC benchmark from reg packet distribution to site initiation. www.linkedin.com/posts/k36-th...

We are proud to collaborate with the Latin American Cooperative Oncology Group (LACOG) on innovative multicenter clinical studies like DORA and the IRONMAN Registry www.linkedin.com/embed/feed/u...

PCCTC investigators publish results from the phase 1b DeLLpro-300 study of tarlatamab in patients with neuroendocrine prostate cancer: aacrjournals.org/clincancerre...

Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for mHSPC Intensified by ARPI: A Multinational Real-World Analysis of the IRONMAN Registry. Story via UroToday: www.urotoday.com/conference-h...

PCCTC investigator Rana McKay, MD, outlines key findings from the phase 2 COMRADE trial via Urology Times www.urologytimes.com/view/rana-mc...

Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management @ucsdhealth.bsky.social #ProstateCancer #PCSM www.onclive.com/view/consens...

Such an honor and so much fun to join the Cancer Clear and Simple @uwhealth.bsky.social Carbone Cancer Center Podcast to discuss liquid biopsies in cancer! cancer.wisc.edu/community-ou...

PCCTC investigator Michael A. Carducci, MD discusses consensus recommendations for PARP inhibitor use in metastatic prostate cancer with Alan Bryce, MD via UroToday: www.urotoday.com/video-lectur...

Learn more about the PCCTC-managed PROMISE, a registry of prostate cancer patients participating in a research study to learn how genetic differences can affect patient outcomes: www.prostatecancerpromise.org

Esteemed PCCTC investigator Dr Rana McKay discusses the exciting developments in biomarker-driven therapy for metastatic castration-sensitive prostate cancer via @onclive.bsky.social: www.onclive.com/view/emergin...

Mark Your Calendar! 🙌🏾🙌🏽🙌🏿 We’re headed to Lagos for the IRONMAN Conference from September 2nd through the 5th. This isn’t just an event, it’s a major milestone in global health and cancer research you won’t want to miss! Register now: surveys.mayoclinic.org/jfe/form/SV_...

PCCTC investigator Dr Rana McKay and colleagues discuss personalizing treatment intensification in metastatic castration-sensitive prostate cancer via @onclive.bsky.social: www.onclive.com/view/persona...

Just published: Analysis from the TRANSFORMER prostate cancer study reveals baseline testosterone could be considered in the treatment selection process when bipolar androgen therapy is an option www.nature.com/articles/s41...

From PCCTC investigator Dr Rana McKay and colleagues, "Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies," published in Eur Urol Oncol www.sciencedirect.com/science/arti...

Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for Metastatic Hormone-Sensitive Prostate Cancer Intensified by Androgen-Receptor Pathway Inhibitors: A Multinational Real-World Analysis of the PCCTC-managed IRONMAN Registry www.urotoday.com/conference-h...

Learn more about TALENT, the PCCTC-managed study of talazoparib with or without enzalutamide in people with #prostatecancer who have previously received abiraterone (NCT06844383): www.pcctc.org/talent

#ASCO25: PCCTC investigator Dr Rana McKay discusses the COMRADE study, "The combination of olaparib with radium-223 demonstrated feasibility, safety, and antitumor activity in patients with metastatic castration-resistant #prostatecancer with bone metastases”